Literature DB >> 1586978

In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.

H N Nguyen1, B U Sevin, H Averette, J Perras, R Hightower, R Ramos, D Donato, M Penalver.   

Abstract

Adozelesin is a derivative of an extremely cytotoxic compound, CC1065. This entirely new class of drug binds preferentially to DNA and facilitates alkylation reaction. In the present study, we used the adenosine triphosphate (ATP) chemosensitivity assay to compare the cytotoxic potency of Adozelesin with that of common chemotherapeutic agents in ten gynecologic-cancer cell lines. Flow cytometry was also used to study its effects on cell-cycle kinetics. The mean drug concentrations required to produce a 50% reduction in ATP levels as compared with controls [IC50] were: Adriamycin, 0.17 +/- 0.06 microM; 4OH-Cytoxan, 18 +/- 3 microM; cisplatin, 17 +/- 7 microM; 5-fluorouracil, 183 +/- 116 microM; and Adozelesin, 11.0 +/- 5.4 pM. Thus, Adozelesin was 10(4) - 10(7) times more potent than Adriamycin, cisplatin, 5-fluorouracil, and Cytoxan. Cell kinetics studies revealed significant S and G2 blocks such as those previously reported for other alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586978     DOI: 10.1007/bf00686483

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  27 in total

1.  Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065.

Authors:  M A Warpehoski; I Gebhard; R C Kelly; W C Krueger; L H Li; J P McGovren; M D Prairie; N Wicnienski; W Wierenga
Journal:  J Med Chem       Date:  1988-03       Impact factor: 7.446

2.  Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors.

Authors:  K R Geisinger; T E Kute; M J Pettenati; C E Welander; Y Dennard; L A Collins; M E Berens
Journal:  Cancer       Date:  1989-01-15       Impact factor: 6.860

3.  Comparison of the chemosensitivity of human neoplastic tissues between succinate dehydrogenase inhibition test and ATP assay.

Authors:  H Anai; Y Maehara; H Kusumoto; K Sugimachi
Journal:  Clin Chim Acta       Date:  1987-06-30       Impact factor: 3.786

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity.

Authors:  D G Martin; C Biles; S A Gerpheide; L J Hanka; W C Krueger; J P McGovren; S A Mizsak; G L Neil; J C Stewart; J Visser
Journal:  J Antibiot (Tokyo)       Date:  1981-09       Impact factor: 2.649

6.  The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability.

Authors:  Y Maehara; H Anai; R Tamada; K Sugimachi
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

7.  A simple and rapid in vitro test for determining sensitivity of cancer cells to anticancer drugs.

Authors:  H Ichihashi; M Nogaki; M Yamauchi; H Takagi; T Kondo; T Ozawa
Journal:  Jpn J Surg       Date:  1986-09

8.  Preliminary toxicity studies with the DNA-binding antibiotic, CC-1065.

Authors:  J P McGovren; G L Clarke; E A Pratt; T F DeKoning
Journal:  J Antibiot (Tokyo)       Date:  1984-01       Impact factor: 2.649

9.  Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations.

Authors:  C A Bertelsen; V K Sondak; B D Mann; E L Korn; D H Kern
Journal:  Cancer       Date:  1984-03-15       Impact factor: 6.860

10.  Synergistic effects of cis-platinum and cytosine arabinoside on ovarian carcinoma cell lines, demonstrated by dual-parameter flow cytometry.

Authors:  R E Kingston; B U Sevin; R Ramos; M Saks; D Donato; M A Jarrell; H E Averette
Journal:  Gynecol Oncol       Date:  1989-03       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.